📊 CYTK Key Takeaways
Is Cytokinetics Inc. (CYTK) a Good Investment?
Cytokinetics exhibits severe financial distress with negative stockholders equity (-$826.6M), catastrophic cash burn (-$151.4M FCF annually), and operating losses exceeding -$180M, significantly outpacing the recent 376% revenue growth ($19.4M). At current burn rates, cash reserves ($129.8M) provide less than 10 months of runway, necessitating capital raises or immediate path to profitability.
Cytokinetics shows headline revenue growth, but the quality of that growth appears weak relative to its financial profile because losses, cash burn, and negative margins remain extreme. The balance sheet is deeply impaired with negative equity and liabilities exceeding assets, while operating and free cash flow indicate the business is still far from self-funding.
Why Buy Cytokinetics Inc. Stock? CYTK Key Strengths
- Exceptional revenue growth of 376.6% YoY indicates market traction and potential commercialization
- Strong short-term liquidity position with 4.21x current ratio
- Adequate cash reserves of $129.8M for near-term operational needs
- Revenue grew 376.6% year over year, indicating strong top-line momentum
- Liquidity is currently solid with a 4.53x current and quick ratio
- The company still holds meaningful cash reserves of $122.52M
CYTK Stock Risks: Cytokinetics Inc. Investment Risks
- Negative stockholders equity of -$826.6M indicates balance sheet insolvency and unsustainable capital structure
- Operating cash burn of -$145.5M annually with only $129.8M cash reserves creates existential survival risk within 1 year
- Long-term debt of $247.2M with negative interest coverage (-4.0x) cannot be serviced from operations
- Operating margin of -948.7% and net margin of -1064.5% indicate business model not yet viable at scale
- Clinical/regulatory execution risk inherent in pharmaceutical development stage company
- Operating margin of -695.4% and net margin of -891.6% show an unsustainable earnings profile
- Negative stockholders equity of -$659.62M reflects substantial balance sheet weakness
- Free cash flow of -$534.82M and operating cash flow of -$510.01M point to heavy ongoing cash burn and likely future financing needs
Key Metrics to Watch
- Runway to cash depletion and timing/success of capital raises
- Path to operating cash flow breakeven and timeline to profitability
- Revenue growth sustainability and gross margin expansion as volumes increase
- Clinical trial outcomes and regulatory approval trajectory for pipeline
- Quarterly operating cash burn and free cash flow trend
- Revenue durability versus operating expense growth
Cytokinetics Inc. (CYTK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.21x current ratio provides a solid financial cushion.
CYTK Profit Margin, ROE & Profitability Analysis
CYTK vs Healthcare Sector: How Cytokinetics Inc. Compares
How Cytokinetics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cytokinetics Inc. Stock Overvalued? CYTK Valuation Analysis 2026
Based on fundamental analysis, Cytokinetics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cytokinetics Inc. Balance Sheet: CYTK Debt, Cash & Liquidity
CYTK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cytokinetics Inc.'s revenue has grown significantly by 25% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.45 indicates the company is currently unprofitable.
CYTK Revenue Growth, EPS Growth & YoY Performance
CYTK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.6M | -$161.4M | $-1.36 |
| Q3 2025 | $463.0K | -$134.4M | $-1.36 |
| Q2 2025 | $249.0K | -$134.4M | $-1.12 |
| Q1 2025 | $835.0K | -$135.6M | $-1.33 |
| Q3 2024 | $378.0K | -$128.6M | $-1.35 |
| Q2 2024 | $249.0K | -$128.6M | $-1.31 |
| Q1 2024 | $835.0K | -$131.3M | $-1.33 |
| Q3 2023 | $378.0K | -$19.8M | $-1.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cytokinetics Inc. Dividends, Buybacks & Capital Allocation
CYTK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cytokinetics Inc. (CIK: 0001061983)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYTK
What is the AI rating for CYTK?
Cytokinetics Inc. (CYTK) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYTK's key strengths?
Claude: Exceptional revenue growth of 376.6% YoY indicates market traction and potential commercialization. Strong short-term liquidity position with 4.21x current ratio. ChatGPT: Revenue grew 376.6% year over year, indicating strong top-line momentum. Liquidity is currently solid with a 4.53x current and quick ratio.
What are the risks of investing in CYTK?
Claude: Negative stockholders equity of -$826.6M indicates balance sheet insolvency and unsustainable capital structure. Operating cash burn of -$145.5M annually with only $129.8M cash reserves creates existential survival risk within 1 year. ChatGPT: Operating margin of -695.4% and net margin of -891.6% show an unsustainable earnings profile. Negative stockholders equity of -$659.62M reflects substantial balance sheet weakness.
What is CYTK's revenue and growth?
Cytokinetics Inc. reported revenue of $19.4M.
Does CYTK pay dividends?
Cytokinetics Inc. does not currently pay dividends.
Where can I find CYTK SEC filings?
Official SEC filings for Cytokinetics Inc. (CIK: 0001061983) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYTK's EPS?
Cytokinetics Inc. has a diluted EPS of $-1.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CYTK a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Cytokinetics Inc. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CYTK stock overvalued or undervalued?
Valuation metrics for CYTK: ROE of N/A (sector avg: 15%), net margin of -1,064.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CYTK stock in 2026?
Our dual AI analysis gives Cytokinetics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CYTK's free cash flow?
Cytokinetics Inc.'s operating cash flow is $-145.5M, with capital expenditures of $5.9M. FCF margin is -782.2%.
How does CYTK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,064.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 4.21 (avg: 2).